A Phase 3 interventional study of Gabapentin in Transient Insomnia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 35 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-02.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders — none open to participants now, none under way, none of them phase 3. Gabapentin · Sleep Initiation and Maintenance Disorders.
Among the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders, this one is the 2nd largest by enrollment, is one of 2 that started in 2006, is one of 9 in phase 3, and was the 2nd registered.
2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →None of the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders is open now. The open studies under Sleep Initiation and Maintenance Disorders, anywhere →
Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →
Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,254 is above the median of 68 across 2,356 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 283 across the 14 interventional studies. Of the 14 that completed or were terminated, 2 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 6 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 9 studies filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess consumers' behaviors related to gabapentin self- selection and use, relative to warnings and directions for use, as described in the proposed over-the-counter (OTC) product label.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Gabapentin
Gabapentin 50 mg oral capsule 30 minutes before bedtime
Proportion of subjects who selected or purchased gabapentin for use (patients had symptoms consistent with indication and no contraindications)
Time frame: Throughout Day 90
Subject compliance with directions for use (number of capsules per dose and the number of doses per day)
Time frame: Throughout Day 90
Adverse events
Time frame: Duration of study
The record gives a start of Aug 2006 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gabapentin
Sleep Initiation and Maintenance Disorders →
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →